JATT stock forecast, quote, news & analysis
JATT II Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses... Show more
JATT II Acquisition Corp (JATT) Stock Analysis: A Biotech SPAC Nearing Its Talawar Combination Vote
Key Takeaways
- JATT II Acquisition Corp (JATT) is a special purpose acquisition company (SPAC) that raised $60 million in an April 2026 initial public offering at $10.00 per share.
- The company has signed a definitive business combination agreement with Talawar TX Inc., a biotechnology company developing TALA-125 for atopic dermatitis.
- The combined company is expected to be renamed Talawar Therapeutics and to trade under the ticker TLWR with roughly $285 million in anticipated gross proceeds.
- JATT shares have eased from about $11.28 to approximately $10.25 over the trailing month, a decline of roughly 9%, as the stock converges toward its per-share trust value.
- The transaction, announced on June 29, 2026, is expected to close in the second half of 2026, subject to shareholder approval and customary closing conditions.
- A $225 million oversubscribed private investment in public equity (PIPE) led by Access Biotechnology anchors the deal's financing.
- For additional detail on JATT's Price Targets, Earnings, and Forecast, explore Tickeron's dedicated pages.
- Explore Trending AI Robots to see top-performing AI trading bots currently drawing attention.
Current Market Snapshot
JATT trades around $10.25, a level that sits modestly above its $10.00 IPO price and roughly in line with its per-share trust value. That positioning is typical of a SPAC that has already announced a business combination and is converging toward its redemption value as the shareholder vote approaches. Daily trading volume is comparatively modest, and the company's market capitalization is roughly $80 million. Because JATT has no operating business of its own, investor sentiment is driven primarily by the pending Talawar combination and by the mechanics of SPAC redemptions rather than by underlying financial results.
JATT II Acquisition Corp (JATT) Business Overview and Competitive Position
JATT II Acquisition Corp is a blank-check company formed in January 2026 and headquartered in Westfield, New Jersey. It is led by Chairman and Chief Executive Officer Dr. Someit Sidhu and Chief Financial Officer Nicholas Fernandez. The SPAC was established to identify and take public a healthcare or healthcare-related business, with a primary emphasis on biotechnology and the broader life sciences sector. Its stated acquisition strategy favors companies applying data-driven approaches such as machine learning and computational biology to drug discovery and development. Dr. Sidhu previously led JATT Acquisition, which completed a business combination with Zura Bio (ZURA) in 2023. JATT II's value proposition rests on its management team's deal-sourcing network and track record rather than on operating assets.
Recent Developments Driving JATT
The defining development for JATT is its June 29, 2026 announcement of a definitive business combination agreement with Talawar TX Inc. Under the terms, the combined company is expected to receive roughly $285 million in gross proceeds before transaction costs and assuming no redemptions, funded through the $60 million held in JATT II's trust account plus a $225 million concurrent PIPE priced at $10.00 per share. The oversubscribed PIPE is led by founding investor Access Biotechnology and includes participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, and Farallon Capital Management.
Talawar is developing TALA-125, an anti-IL-13 and anti-IL-18 bispecific antibody for atopic dermatitis, with clinical entry expected in the first quarter of 2027 and a Phase 2b proof-of-concept readout anticipated in the second half of 2028. In the interim, JATT shares have drifted lower from the low-$12 range toward the $10 level, reflecting the pull of the SPAC redemption mechanism as the merger vote nears and the anticipated closing in the second half of 2026 draws closer.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that collectively monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, holding timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon approaches. Each entry is designed to help traders evaluate automated strategies alongside their own research. Because the list is refreshed to reflect recent performance, it offers a useful snapshot of which algorithmic approaches are currently drawing attention. Explore the Trending AI Robots page to see how AI-driven trading systems are being applied across the market.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important near-term catalyst is completion of the Talawar combination, which hinges on shareholder approval and customary regulatory conditions. The level of redemptions will directly influence the cash ultimately available to the combined company, since redeeming shareholders reduce the proceeds drawn from the trust account. Investors should also monitor the transition of the listing to the TLWR ticker on the Nasdaq Capital Market, along with Talawar's clinical progress for TALA-125, including its planned Phase 1 entry in the first quarter of 2027 and interim Phase 1 data in the fourth quarter of 2027. Broader considerations include competition in the atopic dermatitis market, the biotechnology financing environment, and the combined company's ability to maintain its cash runway through the anticipated Phase 2b readout in 2028.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
JATT in +0.97% Uptrend, advancing for three consecutive days on October 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where JATT advanced for three days, in 22 of 30 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JATT's RSI Oscillator exited the oversold zone, 2 of 3 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for JATT just turned positive on October 21, 2026. Looking at past instances where JATT's MACD turned positive, the stock continued to rise in 11 of 23 cases over the following month. The odds of a continued upward trend are 48%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JATT as a result. In 9 of 33 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 27%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JATT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for JATT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.333) is normal, around the industry mean (-543.087). P/E Ratio (0.000) is within average values for comparable stocks, (118.532). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. JATT's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. JATT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JATT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry FinancialConglomerates